Xu K - Search Results

1

Inactivation of neuronal forebrain A receptors protects dopaminergic neurons in a mouse model of Parkinson's disease.

Carta AR, Kachroo A, Schintu N, Xu K, Schwarzschild MA, Wardas J, Morelli M. Carta AR, et al. Among authors: xu k. J Neurochem. 2009 Dec;111(6):1478-89. doi: 10.1111/j.1471-4159.2009.06425.x. Epub 2009 Oct 8. J Neurochem. 2009. PMID: 19817968 Free PMC article.

2

Neuroprotection by caffeine: time course and role of its metabolites in the MPTP model of Parkinson's disease.

Xu K, Xu YH, Chen JF, Schwarzschild MA. Xu K, et al. Among authors: xu yh. Neuroscience. 2010 May 5;167(2):475-81. doi: 10.1016/j.neuroscience.2010.02.020. Epub 2010 Feb 16. Neuroscience. 2010. PMID: 20167258 Free PMC article.

3

Protection of dopaminergic cells by urate requires its accumulation in astrocytes.

Cipriani S, Desjardins CA, Burdett TC, Xu Y, Xu K, Schwarzschild MA. Cipriani S, et al. Among authors: xu k, xu y. J Neurochem. 2012 Oct;123(1):172-81. doi: 10.1111/j.1471-4159.2012.07820.x. Epub 2012 Aug 22. J Neurochem. 2012. PMID: 22671773 Free PMC article.

4

Neuroprotection by caffeine in the MPTP model of parkinson's disease and its dependence on adenosine A2A receptors.

Xu K, Di Luca DG, Orrú M, Xu Y, Chen JF, Schwarzschild MA. Xu K, et al. Among authors: xu y. Neuroscience. 2016 May 13;322:129-37. doi: 10.1016/j.neuroscience.2016.02.035. Epub 2016 Feb 22. Neuroscience. 2016. PMID: 26905951 Free PMC article.

5

Estrogen prevents neuroprotection by caffeine in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.

Xu K, Xu Y, Brown-Jermyn D, Chen JF, Ascherio A, Dluzen DE, Schwarzschild MA. Xu K, et al. Among authors: xu y. J Neurosci. 2006 Jan 11;26(2):535-41. doi: 10.1523/JNEUROSCI.3008-05.2006. J Neurosci. 2006. PMID: 16407551 Free PMC article.

6

Urate and its transgenic depletion modulate neuronal vulnerability in a cellular model of Parkinson's disease.

Cipriani S, Desjardins CA, Burdett TC, Xu Y, Xu K, Schwarzschild MA. Cipriani S, et al. Among authors: xu k, xu y. PLoS One. 2012;7(5):e37331. doi: 10.1371/journal.pone.0037331. Epub 2012 May 14. PLoS One. 2012. PMID: 22606360 Free PMC article.

7

Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease.

Chen JF, Xu K, Petzer JP, Staal R, Xu YH, Beilstein M, Sonsalla PK, Castagnoli K, Castagnoli N Jr, Schwarzschild MA. Chen JF, et al. Among authors: xu k, xu yh. J Neurosci. 2001 May 15;21(10):RC143. doi: 10.1523/JNEUROSCI.21-10-j0001.2001. J Neurosci. 2001. PMID: 11319241 Free PMC article.

8

Caffeine's neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity shows no tolerance to chronic caffeine administration in mice.

Xu K, Xu YH, Chen JF, Schwarzschild MA. Xu K, et al. Among authors: xu yh. Neurosci Lett. 2002 Mar 29;322(1):13-6. doi: 10.1016/s0304-3940(02)00069-1. Neurosci Lett. 2002. PMID: 11958832

9

Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson's disease.

Schwarzschild MA, Xu K, Oztas E, Petzer JP, Castagnoli K, Castagnoli N Jr, Chen JF. Schwarzschild MA, et al. Among authors: xu k. Neurology. 2003 Dec 9;61(11 Suppl 6):S55-61. doi: 10.1212/01.wnl.0000095214.53646.72. Neurology. 2003. PMID: 14663012 Review.

10

Therapeutic potential of adenosine A(2A) receptor antagonists in Parkinson's disease.

Xu K, Bastia E, Schwarzschild M. Xu K, et al. Pharmacol Ther. 2005 Mar;105(3):267-310. doi: 10.1016/j.pharmthera.2004.10.007. Epub 2004 Dec 21. Pharmacol Ther. 2005. PMID: 15737407 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

12,642 results

Search Page

Filters